Glaxo’s Augmentin Patents Invalidated
- Share via
Bloomberg News
A federal judge invalidated GlaxoSmithKline’s patents for Augmentin, clearing the way for rivals to introduce low-cost versions of the $2-billion-a-year antibiotic.
Generic-drug makers Geneva Pharmaceuticals Inc., a unit of Novartis; Teva Pharmaceuticals Industries Ltd.; and Ranbaxy Laboratories Ltd. sued to invalidate three patents that protect Augmentin from generic competition through December.
Glaxo’s U.S. shares fell $1.56 to $46.39 in NYSE trading.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
